Complex Tuberculous Meningitis: A Case Series Highlighting Rare Co-infections and Severe Complications

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2024 | Volume :01 | Issue : 02 | Page : –
By
vector

Nandlal kumar,

vector

Saumya Singh,

vector

Rajan Pathak,

vector

Pratima Kumari,

vector

Devesh sharma,

vector

Brijnandan Singh,

  1. Assistant Professor, Department of Microbiology, United Institute of Medical Sciences, Prayagraj, Uttar Pradesh, India
  2. Professor & Head, Department of Microbiology, United Institute of Medical Sciences, Prayagraj, Uttar Pradesh, India
  3. Senior Resident, Department of Microbiology, United Institute of Medical Sciences, Prayagraj, Uttar Pradesh, India
  4. Phd.Scholar, Department of Microbiology, United Institute of Medical Sciences, Prayagraj, Uttar Pradesh, India
  5. Professor, Department of Microbiology, United Institute of Medical Sciences, Prayagraj, Uttar Pradesh, India
  6. Assistant Professor, Department of Microbiology, United Institute of Medical Sciences, Prayagraj, Uttar Pradesh, India

Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_114275’);});Edit Abstract & Keyword

This case series presents two complex cases of tuberculous meningitis (TBM) with different complications, illustrating the diverse clinical presentations and management challenges of this disease. Case 1 involves an 18-year-old female with TBM complicated by cryptococcal co-infection, while Case 2 describes a 64-year-old female with TBM complicated by obstructive hydrocephalus and secondary bacterial infections. Both patients had been on anti-tubercular therapy before presentation. Diagnostic approaches included cerebrospinal fluid analysis, cultures, and molecular testing. Management strategies varied based on complications, involving antifungal therapy in Case 1 and neurosurgical intervention in Case 2. Outcomes differed significantly, with Case 1 showing complete symptom resolution and Case 2 resulting in mortality despite aggressive treatment. These cases underscore the importance of maintaining high suspicion for TBM, even in patients on anti-tubercular therapy, and the need for comprehensive diagnostic approaches and tailored treatment strategies. They highlight the potential for severe complications and the complexity of managing TBM.

Keywords: Tuberculous, meningitis, complications,co-infection,treatment

[This article belongs to International Journal of Pathogens (ijpg)]

How to cite this article:
Nandlal kumar, Saumya Singh, Rajan Pathak, Pratima Kumari, Devesh sharma, Brijnandan Singh. Complex Tuberculous Meningitis: A Case Series Highlighting Rare Co-infections and Severe Complications. International Journal of Pathogens. 2024; 01(02):-.
How to cite this URL:
Nandlal kumar, Saumya Singh, Rajan Pathak, Pratima Kumari, Devesh sharma, Brijnandan Singh. Complex Tuberculous Meningitis: A Case Series Highlighting Rare Co-infections and Severe Complications. International Journal of Pathogens. 2024; 01(02):-. Available from: https://journals.stmjournals.com/ijpg/article=2024/view=0

Full Text PDF

Full Text PDF

References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_114275’);});Edit

  1. World Health Organization. Global tuberculosis report 2021: supplementary material. Geneva: World Health Organization; 2022 Mar 31.
  2. Wilkinson RJ, Rohlwink U, Misra UK, Van Crevel R, Mai NT, Dooley KE, et al. Tuberculous meningitis. Nat Rev Neurol. 2017 Oct;13(10):581–98.
  3. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol. 2013 Oct;12(10):999–1010.
  4. Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010 Nov;10(11):803–12.
  5. Garg RK, Sinha MK. Tuberculous meningitis in patients infected with human immunodeficiency virus. J Neurol. 2011 Jan;258:3–13.
  6. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009 Dec;30(4):797–810.
  7. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017 Aug;17(8):873–81.
  8. Mayer-Barber KD, Barber DL. Innate and adaptive cellular immune responses to Mycobacterium tuberculosis infection. Cold Spring Harb Perspect Med. 2015 Dec;5(12):a018424.
  9. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012 Jan;25(1):2–41.
  10. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015 Sep;6:893.
  11. Rajshekhar V. Management of hydrocephalus in patients with tuberculous meningitis. Neurol India. 2009 Jul;57(4):368–74.
  12. Raut T, Garg RK, Jain A, Verma R, Singh MK, Malhotra HS, et al. Hydrocephalus in tuberculous meningitis: incidence, its predictive factors and impact on the prognosis. J Infect. 2013 Apr;66(4):330–7.
  13. Kalita J, Misra UK, Ranjan P. Predictors of long‐term neurological sequelae of tuberculous meningitis: a multivariate analysis. Eur J Neurol. 2007 Jan;14(1):33–7.
  14. Thwaites GE, Chau TT, Stepniewska K, Phu NH, Chuong LV, Sinh DX, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet. 2002 Oct;360(9342):1287–92.
  15. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009 Sep;59(3):167–87.
  16. Bahr NC, Marais S, Caws M, Van Crevel R, Wilkinson RJ, Tyagi JS, et al. GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last. Clin Infect Dis. 2016 May;62(9):1133–5.
  17. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis. 2004 Dec;4:1–4.
  18. World Health Organization. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017.
  19. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb;50(3):291–322.
  20. Misra UK, Kalita J, Srivastava M, Mandal SK. Prognosis of tuberculous meningitis: a multivariate analysis. J Neurol Sci. 1996 Apr;137(1):57–61.
  21. Török ME. Tuberculous meningitis: advances in diagnosis and treatment. Br Med Bull. 2015 Mar;113(1):117–31.
  22. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017 Apr;5(4):291–360.
  23. Thwaites GE, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis. 2005 Jul;192(1):79–88.
  24. Van Well GT, Paes BF, Terwee CB, Springer P, Roord JJ, Donald PR, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the Western Cape of South Africa. Pediatrics. 2009 Jan;123(1):e1–8.
  25. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;(4).
  26. Thwaites GE, Bang ND, Dung NH, Quy HT, Oanh DT, Thoa NT, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004 Oct;351(17):1741–51.
  27. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis. 2010 Nov;90(6):375–92.
  28. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov;200(10):e93–142.
  29. Allegranzi B, Nejad SB, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011 Jan;377(9761):228–41.
  30. World Health Organization. The end TB strategy. Geneva: WHO; 2015.
  31. Thwaites GE, Hien TT. Tuberculous meningitis: many questions, too few answers. Lancet Neurol. 2005 Mar;4(3):160–70.
Regular Issue Subscription Review Article
Volume 01
Issue 02
Received 30/09/2024
Accepted 27/10/2024
Published 05/11/2024
173